GlassScriptPhysician profile
Diwas Shahi
NPI 1053791467
$4,785.29
in general payments reported to CMS, 2019-2025
29 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.94 · 2022: $248 · 2023: $1,213 · 2024: $1,369 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,502.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $938.17 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $499.00 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $369.67 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.12 | 2024-2025 | Dupixent |
| Insmed, INC. | $296.91 | 2024-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $292.47 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.32 | 2022-2025 | Glassia, Cuvitru |
| Grifols USA, LLC | $239.52 | 2023-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.86 | 2022-2025 | Ofev, Jascayd |
| Pulmonx Corporation | $175.36 | 2023-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $125.23 | 2023-2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $113.40 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $101.20 | 2023-2024 | Sunosi |
| Merck Sharp & Dohme LLC | $95.69 | 2024-2025 | Zerbaxa, Dificid |
| Electromed, INC. | $93.32 | 2023-2024 | Smartvest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $91.12 | 2025 | Yupelri |
| Mylan Specialty L.P. | $82.72 | 2023-2024 | Yupelri |
| Baxter Healthcare | $75.06 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pfizer INC. | $67.24 | 2022-2024 | |
| Amgen INC. | $67.13 | 2025 | Tezspire |
| Genentech USA, INC. | $57.44 | 2024 | Xolair |
| Inogen, INC. | $42.42 | 2023-2024 | Inogen At Home Stationary Concentrator |
| United Therapeutics Corporation | $42.39 | 2023-2024 | Tyvaso |
| Philips North America LLC | $38.69 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $21.14 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $19.55 | 2024 | Cresemba |
| Optinose US, INC. | $18.71 | 2024 | |
| Melinta Therapeutics, LLC | $18.30 | 2023 | Vabomere |
| Pharming Healthcare, INC. | $18.14 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diwas Shahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.